Hospital Admission May Raise Health Care Spending in Dementia - Summary - MDSpire

Hospital Admission May Raise Health Care Spending in Dementia

  • By

  • Andrea Surnit

  • June 9, 2026

Share

Objective:

To analyze the impact of hospital admissions following emergency department visits on health care spending and mortality specifically among older patients with dementia.

Key Findings:
  • 55% of emergency department visits resulted in hospital admission.
  • No evidence that hospital admission was associated with lower mortality or fewer subsequent inpatient days.
  • Hospital admission was associated with approximately $2,500 higher health care spending within 30 days and approximately $4,000 higher spending within 90 days, primarily due to increased postacute care services.
  • No meaningful differences in inpatient, outpatient, physician service, or hospice spending were found.
Interpretation:

The findings suggest that hospital admissions may not provide significant value for patients with dementia, as they do not improve mortality or functional outcomes, raising concerns about the appropriateness of such admissions.

Limitations:
  • Key assumptions of the instrumental variable analysis cannot be directly verified, which may affect the reliability of the findings.
  • Findings may not generalize to patients with more severe disease, Medicare Advantage enrollees, or those outside the United States.
  • The study could not assess outcomes such as caregiver burden, which is an important aspect of dementia care.
Conclusion:

The study indicates that some hospital admissions may provide little value among patients with dementia, highlighting the need for future research to explore mechanisms to reduce low-value admissions, particularly focusing on patient outcomes and care strategies.

Original Source(s)

Hospital Admission May Raise Health Care Spending in Dementia

  • by Andrea Surnit

  • June 9, 2026

Related Content

Astigmatism Up After COVID Restrictions

Researchers identified delayed corneal changes in schoolchildren that emerged after myopia rates had already increased during the pandemic.

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.